Fig. 7

Anti-oxidant (NAC) could increase ATP supply for P-gp efflux pumps and compromise MDR-reversal abilities of GO-PEG-OSA in HGC-27/PTX cells. A ROS in GO-PEG-OSA plus NIR-treated HGC-27/PTX cells, with addition of NAC. b MTP GO-PEG-OSA plus NIR-treated HGC-27/PTX cells, with addition of NAC. c Mitochondrial-derived ROS in GO-PEG-OSA plus NIR-treated HGC-27/PTX cells, with addition of NAC. d Relative content of ATP in GO-PEG-OSA plus NIR-treated HGC-27/PTX cells, with addition of NAC. e Relative Rho123 withheld in GO-PEG-OSA plus NIR-treated HGC-27/PTX cells, with addition of NAC or exogenous ATP. f Viabilities of PTX@GO-PEG-OSA-treated HGC-27/PTX cells, with addition of NAC or exogenous ATP. g EdU images and statistics EdU-positive number of PTX@GO-PEG-OSA-treated HGC-27/PTX cells, with addition of NAC or exogenous ATP. Scale bar, 100 µm. h Flow cytometry images and statistics apoptotic number of PTX@GO-PEG-OSA-treated HGC-27/PTX cells, with addition of NAC or exogenous ATP. Data are shown as the mean ± SD, n = 5. ** indicates P < 0.01. *** indicates P < 0.001